Clozapine-induced serositis: Review of its clinical features, pathophysiology and management strategies

Clinical Neuropharmacology

Volumn 32, Issue 4, 2009, Pages 219-223

  Mouaffak, Fayçal ^a,b,c   Gaillard, Raphael ^a,b,c   Burgess, Elizabeth ^a,b,c   Zaki, Hanane ^a,b,c   Olié, Jean Pierre ^a,b,c   Krebs, Marie Odile ^a,b,c  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Ascites; Clozapine; Pericarditis; Pleuritis; Polyserositis

Indexed keywords

AMITRIPTYLINE; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CLOZAPINE; FLUOXETINE; IMMUNOGLOBULIN E; LITHIUM CARBONATE; LORAZEPAM; PAROXETINE; SERTRALINE; TROPONIN I; VALPROIC ACID;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; BIPOLAR DISORDER; CASE REPORT; CELLULITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; ENDURANCE; EOSINOPHILIA; ERYTHROCYTE SEDIMENTATION RATE; HEART PALPITATION; HEPATITIS; HUMAN; HYPEREOSINOPHILIA; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTOSIS; LYMPHOMA; NEUROLEPTIC MALIGNANT SYNDROME; NORMOCHROMIC NORMOCYTIC ANEMIA; PANCREATITIS; PARANOID SCHIZOPHRENIA; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERICARDITIS; PHYSICAL EXAMINATION; PLEURISY; POLYSEROSITIS; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THORAX PAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SEROSITIS; WITHHOLDING TREATMENT;

EID: 68949166181     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318197a2f2     Document Type: Review

References (46)

1. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004;161(9): 1620-1625.
2. Kane JM, Khanna S, Rajadhyaksha S, et al. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2006;21(1):21-28.
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-796.
4. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56(1-2):1-10.
5. Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD000966.
6. Young CR, Bowers MB, Jr., Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381-390.
7. Grohmann R, Ruther E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology (Berl) 1989;(Suppl 99):S101-S104.
8. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61(Suppl 8):14-17; discussion 18-19.
9. Wolf J, Sartorius A, Alm B, et al. Clozapine-induced lupus erythematosus. J Clin Psychopharmacol 2004;24(2):236-238.
10. Malhotra S, Franco K, Tomford JW, et al. Polyserositis, acute withdrawal, and relapse after abrupt clozapine discontinuation. Psychosomatics 2002;43(5):418-420.
11. Murko A, Clarke S, Black DW Clozapine and pericarditis with pericardial effusion. Am J Psychiatry 2002;159(3):494.
12. Waller H, Porter R, Ritz S, et al. Late occurrence of clozapine-associated polyserositis. Int J Neuropsychopharmacol 2007;10(1):147-148.
13. Luo D, McColl P, Walmsley R. Acute onset of ascites with clozapine-induced hepatitis. Intern Med J 2007;37:204-205.
14. Bhatti MA, Zander J, Reeve E. Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash. J Clin Psychiatry 2005;66(11):1490-1491.
15. Daly JM, Goldberg RJ, Braman SS. Polyserositis associated with clozapine treatment. Am J Psychiatry 1992;149(9):1274-1275.
16. Eymin G, Andresen M, Godoy J, et al. [Malignant neuroleptic syndrome and polyserositis associated to clozapine use: report of one case]. Rev Med Chil 2005;133(10):1225-1228.
17. Branik E, Nitschke M. Pericarditis and polyserositis as a side effect of clozapine in an adolescent girl. J Child Adolesc Psychopharmacol 2004; 14(2):311-314.
18. Rathore S, Masani ND, Callaghan PO. Clozapine-induced effuso-constrictive pericarditis. Case report and review of the literature. Cardiology 2007;108(3):183-185.
19. Catalano G, Catalano MC, Frankel Wetter RL. Clozapine induced polyserositis. Clin Neuropharmacol 1997;20(4):352-356.
20. Thompson J, Chengappa KN, Good CB, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998;13(20):95-98.
21. Boot E, de Haan L, Guzelcan Y, et al. Pericardial and bilateral pleural effusion associated with clozapine treatment. Eur Psychiatry 2004;19(1):65.
22. Schonfeldt-Lecuona C, Connemann BJ. Sweet's syndrome and polyserositis with clozapine. Am J Psychiatry 2002;159(11):1947.
23. Wehmeier PM, Heiser P, Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharm Ther 2005;30(1):91-96. (Pubitemid 41602097)
24. Stanislav SW, Gonzalez-Blanco M. Papular rash and bilateral pleural effusion associated with clozapine. Ann Pharmacother 1999;33(9): 1008-1009.
25. Chatterjee A, Safferman AZ. Cellulitis, eosinophilia, and unilateral pleural effusion associated with clozapine treatment. J Clin Psychopharmacol 1997;17(3):232-233.
26. Kay SE, Doery J, Sholl D. Clozapine associated pericarditis and elevated troponin I. Aust N Z J Psychiatry 2002;36(1): 143-144.
27. Khalil N. [Peri-/myocarditis with clozapine (Leponex)]. Psychiatr Prax 1997;24(1):46.
28. Kortner K, Neuhaus AH, Schurer F, et al. Eosinophilia indicating subclinical clozapine-induced pericarditis. J Clin Psychiatry 2007;68(7): 1147-1148.
29. Lim A, Sivakumaran P, Israel M. Clozapine-associated polyserositis. N Z Med J 2003;116(1184):U651.
30. Raju P, Rao GK, Davis G. Pericardial effusion in patients with schizophrenia: Are they on clozapine? Emerg Med J 2008;25(6):383-384.
31. Naranjo CA, Busto U, Sellers EM. Difficulties in assessing adverse drug reactions in clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 1982;6(4-6):65 1-657.
32. Kaufman J, O'Shaughnessy IM. Eosinophilic pleural effusion associated with valproic acid administration. South Med J 1995; 88(8):881-882.
33. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21(1):84-92.
34. Morelock SY, Sahn SA. Drugs and the pleura. Chest 1999;116(1): 212-221.
35. Lowe CM, Grube RR, Scates AC. Characterization and clinical management of clozapine-induced fever. Ann Pharmacother 2007;41(10): 1700-1704.
36. Raaska K, Raitasuo Y Neuvonen PJ. Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration. Eur J Clin Pharmacol 2002;58(9):587-591.
37. Maes M, Bocchio Chiavetto L, Bignotti S, et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002;54(3): 281-291.
38. Maes M, Bosmans E, Kenis G, et al. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997;26(2-3):221-225.
39. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33(5):407-418.
40. Pollmacher T, Haack M, Schuld A, et al. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 2000;34(6):369-382.
41. Pereira A, McLaren A, Bell WR, et al. Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow. Pharmacogenomics J 2003;3(4):227-234.
42. Mosyagin I, Dettling M, Roots I, et al. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24(6):613-617.
43. Liu ZC, Uetrecht JP. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 1995;275(3): 1476-1483.
44. Williams DP, Pirmohamed M, Naisbitt DJ, et al. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 1997;283(3): 1375-1382.
45. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272(3):984-990.
46. Opgen-Rhein C, Dettling M. Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 2008;9(8):1101-1111.